Non-industry sponsored (local) studies:
- Overcoming the negative effect of anti αGAL antibody formation in Fabry disease
- The Fabry Cardio Prediction Study
- Secondary pathophysiology in Fabry disease, Gaucher disease and ASMD
Multicenter clinical trials the AMC participates in:
- Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function (BALANCE)
- Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL (R) (Agalsidase Alfa)
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY)
